Inspire(US:INSP) Globenewswire·2026-01-02 14:56Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of false and misleading statements regarding the launch of its Inspire V device, which has led to significant financial losses for investors [2][4]. Company Overview - Inspire Medical Systems, Inc. is a publicly traded company on the NYSE under the ticker INSP [2]. - The company has faced serious challenges in launching its new Inspire V device, including logistical issues and weak market demand [5][6]. Legal Proceedings - A federal securities class action has been filed against Inspire Medical, with a deadline of January 5, 2026, for investors to seek the role of lead plaintiff [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [7]. Financial Impact - On August 4, 2025, Inspire Medical announced significant setbacks in the launch of the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [5][6]. - Following the announcement, Inspire's stock price plummeted over 32%, from $129.95 per share to $87.91 per share, resulting in a loss of approximately $1.2 billion in market capitalization [6]. Issues with Product Launch - The company reported that the rollout of the Inspire V device was delayed due to treatment centers not completing necessary training and onboarding [5]. - Billing and reimbursement challenges were also highlighted, as Medicare's approval of a CPT code for Inspire V did not coincide with the necessary software updates for claims processing [5]. Call for Information - Faruqi & Faruqi encourages anyone with information regarding Inspire Medical's conduct, including whistleblowers and former employees, to come forward [8].